The Pharmaceutical Treatment of Premature Ejaculation
Abstract
This chapter combines approaches from philosophy of science, agnotology, and information and communication science to investigate the differing views held by countries, on the one hand, and experts, on the other. The semantic ambiguity of premature ejaculation (PE) stems from the fact that both the term and the concept remain largely ill-defined. Sexual medicine is one of the fields in which relationships between scientists and pharmaceutical companies are very close. Therapeutic ambiguity is linked to etiological ambiguity: PE can have several causes and is multifactorial. The fourfold ambiguity uncovered around scientificity and the legality of prescribing dapoxetine is compounded by a strategy whose every medium aims to convince men of a series of subtly intertwined statements and arguments. This gray-zone strategy is a roundabout way of getting people to put pressure on their doctor to prescribe a drug to treat their PE.
Read the paper
Related studies
- Improving the translation of search strategies using the Polyglot Search Translator: a randomized controlled trial
- Nutritional, Physical, Cognitive, and Combination Interventions and Frailty Reversal Among Older Adults: A Randomized Controlled Trial
- Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
- A randomized, controlled trial of oral propranolol in infantile hemangioma
- Clinical phenotypes of delirium during critical illness and severity of subsequent long-term cognitive impairment: a prospective cohort study
- Increased physical activity improves sleep and mood outcomes in inactive people with insomnia: a randomized controlled trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.